Evaluation of an Interprofessional Training Program to Improve Cancer Drug Therapy Safety.

Purpose: Drug therapy for cancer is a high-risk, high-volume clinical intervention that requires interprofessional teams. Given the complexity of anticancer drug therapy and safety concerns, an interdisciplinary team developed a novel training program for oncology registered nurses and pharmacists to improve cancer drug safety.
Methods: Participants completed preworkshop learning assessments and received access to web-based modules on six topics: hazardous drug handling, drug extravasation, hypersensitivity reaction management, sepsis recognition, immune checkpoint inhibitor toxicities, and oral oncolytic adherence. In a 7-hour workshop, participants applied module content in interactive exercises and high-fidelity simulations. Preworkshop and postworkshop questionnaires assessed changes in knowledge and confidence in each topic. Program satisfaction and changes to clinical practice or policies were assessed 3 months after the workshop.
Results: Two hundred ninety-two nurses and 82 pharmacists applied to participate, and 103 (35%) and 44 (54%) have participated, respectively. Long-term follow-up data were available on 133 (90%) participants. Change scores in confidence to meet program objectives increased between pre- and postworkshop (range of increase 0.6-0.8, P < .01). Knowledge scores increased significantly between pre- and postworkshop (average improvement of 3.2 points, P < .01). Overall program satisfaction was high (mean 5.0, standard deviation [0.2] on a five-point scale). Seventy-seven (60%) reported that they had made at least one clinical practice or institutional policy change at 3 months.
Conclusion: An interprofessional education program with online modules, in-person interactive sessions, and simulation activities is a promising strategy to deliver cancer drug safety content to practicing oncology clinicians.
Competing Interests: Karen B. FarrisConsulting or Advisory Role: QuiO, Birth Control PharmacistsResearch Funding: AstraZeneca MiKaela OlsenHonoraria: Becton DickinsonConsulting or Advisory Role: Beckinson and DickersonTravel, Accommodations, Expenses: Becton Dickinson Christopher R. FrieseConsulting or Advisory Role: RTI Health Solutions, LillyResearch Funding: Merck, National Comprehensive Cancer Network/PfizerOther Relationship: Patient-Centered Outcomes Research Institute (PCORI)No other potential conflicts of interest were reported.